San Diego, United States
Biolinq, founded in 2012 and headquartered in the United States, is revolutionizing the field of biotechnology and medical devices with its innovative biowearable technology. Their product, an advanced biosensing platform, uses an array of electrochemical sensors that provide continuous and reliable metabolic health monitoring.
Offering the potential to measure multiple analytes such as glucose, ketones, and lactate, Biolinq promises users actionable insights into their metabolic health. With a mission to bring biosensing and biowearables mainstream over the next decade, their solutions are setting new standards in personal health monitoring.
In a recent capital infusion, Biolinq secured a $58.00M Series D investment on April 4, 2024. Key investors include RiverVest, Pegasus Tech Ventures, Senvest Capital, and AXA Investment Managers. This capital is expected to further propel their growth and innovation in the dynamic landscape of health-focused wearable tech.
